|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
|
JPH10338658A
(ja)
*
|
1997-04-08 |
1998-12-22 |
Hoechst Marion Roussel Kk |
レチノイド作用調節剤
|
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756235A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
CA2340068A1
(en)
*
|
1998-08-12 |
2000-02-24 |
Smithkline Beecham Corporation |
Calcilytic compounds
|
|
DE19908483A1
(de)
*
|
1999-02-26 |
2000-10-05 |
Klinge Co Chem Pharm Fab |
Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
|
|
EP1031564A1
(en)
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
JP2004507465A
(ja)
*
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
AU2001290143A1
(en)
|
2000-09-29 |
2002-04-08 |
Glaxo Group Limited |
Morpholin-acetamide derivatives for the treatment of inflammatory diseases
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
GB0207445D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Glaxo Group Ltd |
Novel compounds
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
WO2006097817A1
(en)
|
2005-03-17 |
2006-09-21 |
Pfizer Japan Inc. |
N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
|
|
PE20071159A1
(es)
|
2005-10-31 |
2007-11-30 |
Schering Corp |
Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
|
|
US8067457B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
US8067415B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
HUP0600809A3
(en)
*
|
2006-10-27 |
2008-09-29 |
Richter Gedeon Nyrt |
New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
WO2009156421A1
(en)
|
2008-06-24 |
2009-12-30 |
Topotarget A/S |
Squaric acid derivatives as inhibitors of the nicotinamide
|
|
EP2342181A1
(en)
|
2008-08-29 |
2011-07-13 |
Topo Target A/S |
Novel urea and thiourea derivatives
|
|
EP2453883A1
(en)
|
2009-07-17 |
2012-05-23 |
Topo Target A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
CN106243023A
(zh)
|
2010-09-03 |
2016-12-21 |
福马Tm有限责任公司 |
用于抑制nampt的胍化合物和组合物
|
|
CA2809391A1
(en)
|
2010-09-03 |
2012-03-08 |
Genentech, Inc. |
4-{[(pyridin-3-yl-methyl)aminocarbonyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
|
|
SG188367A1
(en)
|
2010-09-03 |
2013-04-30 |
Forma Tm Llc |
Novel compounds and compositions for the inhibition of nampt
|
|
CN103189356B
(zh)
*
|
2010-09-29 |
2015-11-25 |
英特维特国际股份有限公司 |
N-杂芳基化合物
|
|
JP6117104B2
(ja)
|
2010-11-15 |
2017-04-19 |
アッヴィ・インコーポレイテッド |
Ｎａｍｐｔおよびｒｏｃｋ阻害薬
|
|
WO2012067963A1
(en)
|
2010-11-15 |
2012-05-24 |
Abbott Laboratories |
Nampt inhibitors
|
|
AU2011367222B2
(en)
|
2011-05-04 |
2017-04-13 |
Forma Tm, Llc |
Novel compounds and compositions for the inhibition of NAMPT
|
|
BR112013028877A2
(pt)
|
2011-05-09 |
2017-01-31 |
Forma Tm Llc |
derivados de piperidina e composições para a inibição de nicotinamida fosforibosiltransferase (nampt)
|
|
CA2873097A1
(en)
|
2012-05-11 |
2013-11-14 |
Todd M. Hansen |
Pyridazine and pyridine derivatives as nampt inhibitors
|
|
CN104684906B
(zh)
|
2012-05-11 |
2017-06-09 |
艾伯维公司 |
Nampt抑制剂
|
|
HK1208450A1
(en)
|
2012-05-11 |
2016-03-04 |
Abbvie Inc. |
Nampt inhibitors
|
|
US9334264B2
(en)
|
2012-05-11 |
2016-05-10 |
Abbvie Inc. |
NAMPT inhibitors
|
|
HK1215579A1
(zh)
|
2012-11-29 |
2016-09-02 |
Karyopharm Therapeutics, Inc. |
被取代的2，3-二氫苯並呋喃基化合物和其用途
|
|
KR102325247B1
(ko)
|
2013-07-03 |
2021-11-11 |
카리오팜 쎄라퓨틱스, 인코포레이티드 |
치환된 벤조퓨라닐 및 벤즈옥사졸릴 화합물 및 이의 용도
|
|
US9994558B2
(en)
|
2013-09-20 |
2018-06-12 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
CN108137563A
(zh)
|
2015-08-18 |
2018-06-08 |
卡尔约药物治疗公司 |
用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
TWI835714B
(zh)
|
2016-10-18 |
2024-03-21 |
美商思進公司 |
菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
BR112019022445A2
(pt)
|
2017-04-27 |
2020-05-12 |
Seattle Genetics, Inc. |
Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco
|
|
WO2019149637A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
KR20250107972A
(ko)
|
2018-05-04 |
2025-07-14 |
레미디 플랜, 인크. |
암 줄기 세포를 표적화하는 암 치료
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
BR112022008753A2
(pt)
|
2019-11-06 |
2022-07-19 |
Remedy Plan Inc |
Tratamentos de câncer direcionados a células-tronco cancerosas
|
|
US20240376074A1
(en)
|
2021-05-13 |
2024-11-14 |
Remedy Plan, Inc. |
Nampt inhibitors and uses thereof
|